Published in PLoS One on February 04, 2010
A long neglected world malaria map: Plasmodium vivax endemicity in 2010. PLoS Negl Trop Dis (2012) 5.24
Determinants of relapse periodicity in Plasmodium vivax malaria. Malar J (2011) 4.00
Using serological measures to monitor changes in malaria transmission in Vanuatu. Malar J (2010) 2.47
Malaria rapid diagnostic tests in elimination settings--can they find the last parasite? Clin Microbiol Infect (2011) 1.98
The anaemia of Plasmodium vivax malaria. Malar J (2012) 1.82
Identification and prioritization of merozoite antigens as targets of protective human immunity to Plasmodium falciparum malaria for vaccine and biomarker development. J Immunol (2013) 1.68
Features and prognosis of severe malaria caused by Plasmodium falciparum, Plasmodium vivax and mixed Plasmodium species in Papua New Guinean children. PLoS One (2011) 1.55
Multiplicity and diversity of Plasmodium vivax infections in a highly endemic region in Papua New Guinea. PLoS Negl Trop Dis (2011) 1.47
Force of infection is key to understanding the epidemiology of Plasmodium falciparum malaria in Papua New Guinean children. Proc Natl Acad Sci U S A (2012) 1.33
How much remains undetected? Probability of molecular detection of human Plasmodia in the field. PLoS One (2011) 1.23
Intermittent preventive treatment for malaria in Papua New Guinean infants exposed to Plasmodium falciparum and P. vivax: a randomized controlled trial. PLoS Med (2012) 1.20
Systematic review of sub-microscopic P. vivax infections: prevalence and determining factors. PLoS Negl Trop Dis (2015) 1.19
Blood-Stage Parasitaemia and Age Determine Plasmodium falciparum and P. vivax Gametocytaemia in Papua New Guinea. PLoS One (2015) 1.15
Red blood cell polymorphism and susceptibility to Plasmodium vivax. Adv Parasitol (2013) 1.15
A Large Plasmodium vivax Reservoir and Little Population Structure in the South Pacific. PLoS One (2013) 1.07
Acquisition of antibodies against Plasmodium falciparum merozoites and malaria immunity in young children and the influence of age, force of infection, and magnitude of response. Infect Immun (2014) 1.06
A high force of plasmodium vivax blood-stage infection drives the rapid acquisition of immunity in papua new guinean children. PLoS Negl Trop Dis (2013) 1.04
Characterization of Plasmodium vivax-associated admissions to reference hospitals in Brazil and India. BMC Med (2015) 1.00
Molecular and epidemiological characterization of Plasmodium vivax recurrent infections in southern Mexico. Parasit Vectors (2013) 1.00
Severe anemia in Papua New Guinean children from a malaria-endemic area: a case-control etiologic study. PLoS Negl Trop Dis (2012) 1.00
Plasmodium vivax Diversity and Population Structure across Four Continents. PLoS Negl Trop Dis (2015) 0.96
High levels of genetic diversity of Plasmodium falciparum populations in Papua New Guinea despite variable infection prevalence. Am J Trop Med Hyg (2013) 0.96
Naturally acquired immune responses to P. vivax merozoite surface protein 3α and merozoite surface protein 9 are associated with reduced risk of P. vivax malaria in young Papua New Guinean children. PLoS Negl Trop Dis (2013) 0.95
Serologic markers in relation to parasite exposure history help to estimate transmission dynamics of Plasmodium vivax. PLoS One (2011) 0.93
Research challenges and gaps in malaria knowledge in Papua New Guinea. Acta Trop (2011) 0.92
A new high-throughput method for simultaneous detection of drug resistance associated mutations in Plasmodium vivax dhfr, dhps and mdr1 genes. Malar J (2011) 0.92
Estimating the numbers of malaria infections in blood samples using high-resolution genotyping data. PLoS One (2012) 0.92
A systematic review of sub-microscopic Plasmodium vivax infection. Malar J (2015) 0.87
An Antibody Screen of a Plasmodium vivax Antigen Library Identifies Novel Merozoite Proteins Associated with Clinical Protection. PLoS Negl Trop Dis (2016) 0.87
Novel Cross-Border Approaches to Optimise Identification of Asymptomatic and Artemisinin-Resistant Plasmodium Infection in Mobile Populations Crossing Cambodian Borders. PLoS One (2015) 0.85
Tolerability and safety of primaquine in Papua New Guinean children 1 to 10 years of age. Antimicrob Agents Chemother (2012) 0.83
Immunity to malaria in Plasmodium vivax infection: a study in central China. PLoS One (2012) 0.81
Finding the sweet spots of inhibition: understanding the targets of a functional antibody against Plasmodium vivax Duffy binding protein. Int J Parasitol (2012) 0.81
Platform for Plasmodium vivax vaccine discovery and development. Mem Inst Oswaldo Cruz (2011) 0.81
Predicting antidisease immunity using proteome arrays and sera from children naturally exposed to malaria. Mol Cell Proteomics (2014) 0.81
Defining the relationship between Plasmodium vivax parasite rate and clinical disease. Malar J (2015) 0.80
Malaria and immunity during pregnancy and postpartum: a tale of two species. Parasitology (2015) 0.80
Plasmodium vivax Reticulocyte Binding Proteins Are Key Targets of Naturally Acquired Immunity in Young Papua New Guinean Children. PLoS Negl Trop Dis (2016) 0.79
Significant geographical differences in prevalence of mutations associated with Plasmodium falciparum and Plasmodium vivax drug resistance in two regions from Papua New Guinea. Malar J (2015) 0.79
The Incidence and Differential Seasonal Patterns of Plasmodium vivax Primary Infections and Relapses in a Cohort of Children in Papua New Guinea. PLoS Negl Trop Dis (2016) 0.78
Identification of different malaria patterns due to Plasmodium falciparum and Plasmodium vivax in Ethiopian children: a prospective cohort study. Malar J (2016) 0.78
Malaria epidemiology in Lihir Island, Papua New Guinea. Malar J (2013) 0.77
Influence of age on the haemoglobin concentration of malaria-infected patients in a reference centre in the Brazilian Amazon. Mem Inst Oswaldo Cruz (2014) 0.77
A simulation model of the within-host dynamics of Plasmodium vivax infection. Malar J (2015) 0.77
Spatial Effects on the Multiplicity of Plasmodium falciparum Infections. PLoS One (2016) 0.75
Household level spatio-temporal analysis of Plasmodium falciparum and Plasmodium vivax malaria in Ethiopia. Parasit Vectors (2017) 0.75
Naturally Acquired Binding-Inhibitory Antibodies to Plasmodium vivax Duffy Binding Protein and Clinical Immunity to Malaria in Rural Amazonians. J Infect Dis (2016) 0.75
Implications of Plasmodium vivax Biology for Control, Elimination, and Research. Am J Trop Med Hyg (2016) 0.75
Naturally acquired antibody responses to more than 300 Plasmodium vivax proteins in three geographic regions. PLoS Negl Trop Dis (2017) 0.75
The complex relationship of exposure to new Plasmodium infections and incidence of clinical malaria in Papua New Guinea. Elife (2017) 0.75
IgG antibodies to synthetic GPI are biomarkers of immune-status to both Plasmodium falciparum and Plasmodium vivax malaria in young children. Malar J (2017) 0.75
Micro-heterogeneity of malaria transmission in the Peruvian Amazon: a baseline assessment underlying a population-based cohort study. Malar J (2017) 0.75
Insecticide-treated bed nets and curtains for preventing malaria. Cochrane Database Syst Rev (2004) 28.04
The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg (2001) 11.74
Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. PLoS Med (2008) 6.61
Invasion of red blood cells by malaria parasites. Cell (2006) 5.94
The epidemiology of malaria in a Karen population on the western border of Thailand. Trans R Soc Trop Med Hyg (1996) 5.35
Plasmodium vivax and mixed infections are associated with severe malaria in children: a prospective cohort study from Papua New Guinea. PLoS Med (2008) 5.29
A trial of combination antimalarial therapies in children from Papua New Guinea. N Engl J Med (2008) 4.77
Immunity to non-cerebral severe malaria is acquired after one or two infections. Nat Med (1999) 4.18
Immune effector mechanisms in malaria. Parasite Immunol (2006) 3.43
Antigenic variation in Plasmodium falciparum. Annu Rev Microbiol (2008) 3.10
Malaria morbidity, treatment-seeking behaviour, and mortality in a cohort of young children in rural Burkina Faso. Trop Med Int Health (2003) 3.07
Association of early interferon-gamma production with immunity to clinical malaria: a longitudinal study among Papua New Guinean children. Clin Infect Dis (2008) 2.80
The risk of malarial infections and disease in Papua New Guinean children. Am J Trop Med Hyg (2007) 2.72
Diagnosing infection levels of four human malaria parasite species by a polymerase chain reaction/ligase detection reaction fluorescent microsphere-based assay. Am J Trop Med Hyg (2006) 2.42
The effect of distance from home on attendance at a small rural health centre in Papua New Guinea. Int J Epidemiol (1998) 2.41
The epidemiology of malaria in the Wosera area, East Sepik Province, Papua New Guinea, in preparation for vaccine trials. I. Malariometric indices and immunity. Ann Trop Med Parasitol (1995) 2.24
Immunoglobulin G subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitemia and protection from symptomatic illness. Infect Immun (2009) 2.22
The interaction between Plasmodium falciparum and P. vivax in children on Espiritu Santo island, Vanuatu. Trans R Soc Trop Med Hyg (1997) 2.12
Molecules on the surface of the Plasmodium falciparum infected erythrocyte and their role in malaria pathogenesis and immune evasion. Mol Biochem Parasitol (2001) 1.99
The role of antibodies to Plasmodium falciparum-infected-erythrocyte surface antigens in naturally acquired immunity to malaria. Trends Microbiol (2002) 1.95
Changing patterns of Plasmodium blood-stage infections in the Wosera region of Papua New Guinea monitored by light microscopy and high throughput PCR diagnosis. Am J Trop Med Hyg (2006) 1.93
Measurement of malarial infectivity of human populations to mosquitoes in the Madang area, Papua, New Guinea. Parasitology (1988) 1.89
Development of a multiplex PCR-ligase detection reaction assay for diagnosis of infection by the four parasite species causing malaria in humans. J Clin Microbiol (2004) 1.80
Naturally acquired and vaccine-elicited antibodies block erythrocyte cytoadherence of the Plasmodium vivax Duffy binding protein. Infect Immun (2000) 1.64
Clinical immunity to malaria. Curr Mol Med (2006) 1.63
Naturally acquired Duffy-binding protein-specific binding inhibitory antibodies confer protection from blood-stage Plasmodium vivax infection. Proc Natl Acad Sci U S A (2008) 1.63
Associations of peak shifts in age--prevalence for human malarias with bednet coverage. Trans R Soc Trop Med Hyg (2001) 1.58
The epidemiology of malaria in the Wosera area, East Sepik Province, Papua New Guinea, in preparation for vaccine trials. II. Mortality and morbidity. Ann Trop Med Parasitol (1995) 1.58
Age-acquired immunity to a Plasmodium vivax invasion ligand, the duffy binding protein. J Infect Dis (2002) 1.53
A retrospective examination of secondary sporozoite- and trophozoite-induced infections with Plasmodium falciparum: development of parasitologic and clinical immunity following secondary infection. Am J Trop Med Hyg (1999) 1.51
Immunity to asexual blood stage malaria and vaccine approaches. Immunol Cell Biol (2002) 1.51
A retrospective examination of reinfection of humans with Plasmodium vivax. Am J Trop Med Hyg (2004) 1.38
A retrospective examination of the effect of fever and microgametocyte count on mosquito infection on humans infected with Plasmodium vivax. Am J Trop Med Hyg (2004) 1.37
Plasmodium vivax malaria vaccine development. Mol Immunol (2001) 1.36
Dynamics of malaria parasitaemia associated with febrile illness in children from a rural area of Madang, Papua New Guinea. Trans R Soc Trop Med Hyg (1994) 1.32
Immune responses to asexual blood-stages of malaria parasites. Curr Mol Med (2006) 1.28
Patterns of acquired anti-malarial immunity in Sri Lanka. Mem Inst Oswaldo Cruz (1994) 1.26
The late biting habit of parous Anopheles mosquitoes and pre-bedtime exposure of humans to infective female mosquitoes. Trans R Soc Trop Med Hyg (1996) 1.25
Longitudinal study of Plasmodium falciparum and Plasmodium vivax in a Karen population in Thailand. Malar J (2008) 1.25
Permethrin-impregnated bed nets for the prevention of malaria in schoolchildren on the Thai-Burmese border. Trans R Soc Trop Med Hyg (1994) 1.24
Cellular tumor necrosis factor, gamma interferon, and interleukin-6 responses as correlates of immunity and risk of clinical Plasmodium falciparum malaria in children from Papua New Guinea. Infect Immun (2009) 1.20
Pathogenesis of Plasmodium falciparum malaria: the roles of parasite adhesion and antigenic variation. Cell Mol Life Sci (2002) 1.16
Plasmodium vivax and the importance of the subtelomeric multigene vir superfamily. Trends Parasitol (2008) 1.14
Three different Plasmodium species show similar patterns of clinical tolerance of malaria infection. Malar J (2009) 1.09
Are insecticide-treated bednets more protective against Plasmodium falciparum than Plasmodium vivax-infected mosquitoes? Malar J (2006) 1.00
Differences in human antibody reactivity to Plasmodium falciparum variant surface antigens are dependent on age and malaria transmission intensity in northeastern Tanzania. Infect Immun (2008) 0.97
Accuracy of CT colonography for detection of large adenomas and cancers. N Engl J Med (2008) 9.32
A trial of combination antimalarial therapies in children from Papua New Guinea. N Engl J Med (2008) 4.77
Analysis of Plasmodium falciparum diversity in natural infections by deep sequencing. Nature (2012) 4.37
Genome-wide and fine-resolution association analysis of malaria in West Africa. Nat Genet (2009) 4.30
A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J Infect Dis (2002) 4.14
Mass treatment with single-dose azithromycin for yaws. N Engl J Med (2015) 3.84
Reported reasons for not using a mosquito net when one is available: a review of the published literature. Malar J (2011) 3.16
The peopling of the Pacific from a bacterial perspective. Science (2009) 3.14
Association of early interferon-gamma production with immunity to clinical malaria: a longitudinal study among Papua New Guinean children. Clin Infect Dis (2008) 2.80
The risk of malarial infections and disease in Papua New Guinean children. Am J Trop Med Hyg (2007) 2.72
Monkey malaria in a European traveler returning from Malaysia. Emerg Infect Dis (2008) 2.32
Immunoglobulin G subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitemia and protection from symptomatic illness. Infect Immun (2009) 2.22
Optimization and validation of multi-coloured capillary electrophoresis for genotyping of Plasmodium falciparum merozoite surface proteins (msp1 and 2). Malar J (2009) 2.22
Geographical structure of diversity and differences between symptomatic and asymptomatic infections for Plasmodium falciparum vaccine candidate AMA1. Infect Immun (2003) 2.02
Molecular evidence for the localization of Plasmodium falciparum immature gametocytes in bone marrow. Blood (2013) 2.01
Identification and differentiation of Leishmania species in clinical samples by PCR amplification of the miniexon sequence and subsequent restriction fragment length polymorphism analysis. J Clin Microbiol (2003) 1.96
Distinct protein classes including novel merozoite surface antigens in Raft-like membranes of Plasmodium falciparum. J Biol Chem (2005) 1.95
Evaluation of Plasmodium vivax genotyping markers for molecular monitoring in clinical trials. J Infect Dis (2009) 1.95
Changing patterns of Plasmodium blood-stage infections in the Wosera region of Papua New Guinea monitored by light microscopy and high throughput PCR diagnosis. Am J Trop Med Hyg (2006) 1.93
Rise in malaria incidence rates in South Africa: a small-area spatial analysis of variation in time trends. Am J Epidemiol (2002) 1.88
Identification and stoichiometry of glycosylphosphatidylinositol-anchored membrane proteins of the human malaria parasite Plasmodium falciparum. Mol Cell Proteomics (2006) 1.86
Comparison of PCR-RFLP and Genescan-based genotyping for analyzing infection dynamics of Plasmodium falciparum. Am J Trop Med Hyg (2006) 1.86
Diagnostic genotyping of Old and New World Leishmania species by PCR-RFLP. Diagn Microbiol Infect Dis (2003) 1.86
Parvovirus B19 infection contributes to severe anemia in young children in Papua New Guinea. J Infect Dis (2006) 1.82
MyD88 is essential for clearance of Leishmania major: possible role for lipophosphoglycan and Toll-like receptor 2 signaling. Eur J Immunol (2003) 1.82
Improved laboratory capacity is required to respond better to future cholera outbreaks in Papua New Guinea. Western Pac Surveill Response J (2012) 1.79
Association between naturally acquired antibodies to erythrocyte-binding antigens of Plasmodium falciparum and protection from malaria and high-density parasitemia. Clin Infect Dis (2010) 1.79
Blood-stage Plasmodium infection induces CD8+ T lymphocytes to parasite-expressed antigens, largely regulated by CD8alpha+ dendritic cells. Proc Natl Acad Sci U S A (2008) 1.73
NK cells stimulate recruitment of CXCR3+ T cells to the brain during Plasmodium berghei-mediated cerebral malaria. J Immunol (2007) 1.69
Identification and prioritization of merozoite antigens as targets of protective human immunity to Plasmodium falciparum malaria for vaccine and biomarker development. J Immunol (2013) 1.68
Strategies for detection of Plasmodium species gametocytes. PLoS One (2013) 1.67
Comparison of Plasmodium falciparum allelic frequency distribution in different endemic settings by high-resolution genotyping. Malar J (2009) 1.67
Plasmodium falciparum msp1, msp2 and glurp allele frequency and diversity in sub-Saharan Africa. Malar J (2011) 1.66
Pharmacokinetics and efficacy of piperaquine and chloroquine in Melanesian children with uncomplicated malaria. Antimicrob Agents Chemother (2007) 1.64
Clinical immunity to malaria. Curr Mol Med (2006) 1.63
Naturally acquired Duffy-binding protein-specific binding inhibitory antibodies confer protection from blood-stage Plasmodium vivax infection. Proc Natl Acad Sci U S A (2008) 1.63
IP-10-mediated T cell homing promotes cerebral inflammation over splenic immunity to malaria infection. PLoS Pathog (2009) 1.61
Plasmodium falciparum erythrocyte membrane protein-1 specifically suppresses early production of host interferon-gamma. Cell Host Microbe (2007) 1.61
Comparison of diagnostic methods for the detection and quantification of the four sympatric Plasmodium species in field samples from Papua New Guinea. Malar J (2010) 1.60
Features and prognosis of severe malaria caused by Plasmodium falciparum, Plasmodium vivax and mixed Plasmodium species in Papua New Guinean children. PLoS One (2011) 1.55
Regulation of murine cerebral malaria pathogenesis by CD1d-restricted NKT cells and the natural killer complex. Immunity (2003) 1.54
Putative IKDCs are functionally and developmentally similar to natural killer cells, but not to dendritic cells. J Exp Med (2007) 1.49
Multiplicity and diversity of Plasmodium vivax infections in a highly endemic region in Papua New Guinea. PLoS Negl Trop Dis (2011) 1.47
Multilocus haplotypes reveal variable levels of diversity and population structure of Plasmodium falciparum in Papua New Guinea, a region of intense perennial transmission. Malar J (2010) 1.47
Ownership and usage of mosquito nets after four years of large-scale free distribution in Papua New Guinea. Malar J (2012) 1.45
Reduced Plasmodium vivax erythrocyte infection in PNG Duffy-negative heterozygotes. PLoS One (2007) 1.45
CD4+ CD25+ regulatory T cells suppress CD4+ T-cell function and inhibit the development of Plasmodium berghei-specific TH1 responses involved in cerebral malaria pathogenesis. Infect Immun (2007) 1.42
Severe malarial anemia of low parasite burden in rodent models results from accelerated clearance of uninfected erythrocytes. Blood (2005) 1.39
Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children. Vaccine (2003) 1.39
Murine cerebral malaria development is independent of toll-like receptor signaling. Am J Pathol (2007) 1.38
Force of infection is key to understanding the epidemiology of Plasmodium falciparum malaria in Papua New Guinean children. Proc Natl Acad Sci U S A (2012) 1.33
Acquired immune responses to Plasmodium falciparum merozoite surface protein-1 in the human fetus. J Immunol (2002) 1.32
Population pharmacokinetics of artemether, lumefantrine, and their respective metabolites in Papua New Guinean children with uncomplicated malaria. Antimicrob Agents Chemother (2011) 1.32
Enhanced detection of gametocytes by magnetic deposition microscopy predicts higher potential for Plasmodium falciparum transmission. Malar J (2008) 1.28
Polymerase chain reaction diagnosis and the changing pattern of vector ecology and malaria transmission dynamics in papua new Guinea. Am J Trop Med Hyg (2004) 1.28
Efficacy of sulfadoxine-pyrimethamine in Tanzania after two years as first-line drug for uncomplicated malaria: assessment protocol and implication for treatment policy strategies. Malar J (2005) 1.26
Evidence that the erythrocyte invasion ligand PfRh2 is a target of protective immunity against Plasmodium falciparum malaria. J Immunol (2010) 1.26
Mass drug administration trial to eliminate lymphatic filariasis in Papua New Guinea: changes in microfilaremia, filarial antigen, and Bm14 antibody after cessation. Am J Trop Med Hyg (2008) 1.25
Murine cerebral malaria: the whole story. Trends Parasitol (2010) 1.24
Desbutyl-lumefantrine is a metabolite of lumefantrine with potent in vitro antimalarial activity that may influence artemether-lumefantrine treatment outcome. Antimicrob Agents Chemother (2011) 1.24
How much remains undetected? Probability of molecular detection of human Plasmodia in the field. PLoS One (2011) 1.23
Defining the antigenic diversity of Plasmodium falciparum apical membrane antigen 1 and the requirements for a multi-allele vaccine against malaria. PLoS One (2012) 1.23
Relapses contribute significantly to the risk of Plasmodium vivax infection and disease in Papua New Guinean children 1-5 years of age. J Infect Dis (2012) 1.23
Rapid microarray-based method for monitoring of all currently known single-nucleotide polymorphisms associated with parasite resistance to antimalaria drugs. J Clin Microbiol (2007) 1.22